Patents by Inventor Ruth Geva

Ruth Geva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7560426
    Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: July 14, 2009
    Assignees: HSC Research and Development Limited Partnership, Ontario Cancer Institute
    Inventors: Clifford A. Lingwood, Ruth Geva, legal representative, Leorah Kroyanker, legal representative, Richard Hill, Hannah Farkas-Himsley
  • Publication number: 20070160535
    Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.
    Type: Application
    Filed: March 12, 2007
    Publication date: July 12, 2007
    Inventors: Clifford Lingwood, Hannah Farkas-Himsley, Ruth Geva, Leorah Kroyanker, Richard Hill
  • Patent number: 7208468
    Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: April 24, 2007
    Assignees: HSC Research and Development Limited Partnership, Ontario Cancer Institute
    Inventors: Clifford A. Lingwood, Ruth Geva, legal representative, Leorah Kroyanker, legal representative, Richard Hill, Hannah Farkas-Himsley, deceased
  • Publication number: 20050130895
    Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.
    Type: Application
    Filed: November 12, 2004
    Publication date: June 16, 2005
    Inventors: Clifford Lingwood, Hannah Farkas-Himsley, Ruth Geva, Leorah Kroyanker, Richard Hill
  • Patent number: 5968894
    Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1 and their pentameric subunit B, have been found to be useful in the treatment of mammalian neoplasia, particularly, brain cancer, ovarian cancer, breast cancer and skin cancer. Although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo. Use of a sensitizer, such as sodium butyrate, enhances the efficacy of verotoxins and their subunit B.
    Type: Grant
    Filed: November 28, 1995
    Date of Patent: October 19, 1999
    Inventors: Clifford A. Lingwood, Richard Hill, Hannah Farkas-Himsley, deceased, Ruth Geva, Leorah Kroyanker